Skip to main content

Table 1 Demographic data and laboratory findings at baseline in four subgroups of rheumatoid arthritis patients according to therapeutic agents used

From: Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis

 

Adalimumab (n = 32)

Etanercept (n = 16)

Tocilizumab (n = 24)

Without biologic (n = 20)

Mean age, years

53.5 ± 12.6

54.4 ± 7.8

56.8 ± 14.4

57.0 ± 11.4

Female proportion

28 (87.5%)

13 (81.3%)

20 (83.3%)

17 (85.0%)

Disease duration, years

13.4 ± 6.6

13.6 ± 9.0

13.0 ± 9.7

12.3 ± 5.8

Body mass index, kg/m2

24.8 ± 4.6

23.6 ± 4.5

24.5 ± 3.7

22.9 ± 2.9

RF positivity

28 (87.5%)

13 (81.3%)

17 (70.8%)

14 (70.0%)

Anti-CCP positivity

21 (65.6%)

11 (68.8%)

17 (70.8%)

15 (75.0%)

Baseline ESR, mm/1st hour

33.5 ± 23.4

39.0 ± 36.0

42.5 ± 30.0

35.8 ± 22.1

Baseline DAS28

5.46 ± 0.94

5.48 ± 0.98

5.80 ± 0.85

5.12 ± 0.59

Daily steroid dose, mg/day

6.3 ± 2.5

6.9 ± 1.9

7.4 ± 2.1

7.0 ± 2.2

DMARDs at baseline

    

  MTX, weekly dose, mg

12.0 ± 2.5

10.6 ± 3.7

11.5 ± 2.5

11.3 ± 2.8

  Sulfasalazine

27 (84.4%)

12 (75.0%)

18 (75.0%)

17 (85.0%)

  Hydroxychloroquine

24 (75.0%)

12 (75.0%)

19 (79.2%)

18 (90.0%)

  Cyclosporine

6 (18.7%)

4 (25.0%)

5 (20.8%)

7 (35.0%)

Hypertension

14 (43.8%)

6 (37.5%)

8 (33.3%)

8 (40.0%)

Antihypertensive Rx

8 (25.0%)

4 (25.0%)

7 (29.2%)

6 (30.0%)

Diabetes mellitus

2 (6.2%)

1 (6.3%)

1 (4.2%)

1 (5.0%)

Hypoglycemic Rx

1 (3.1%)

1 (6.3%)

0 (0.0%)

0 (0.0%)

Current smoker

3 (9.4%)

2 (16.6%)

3 (12.5%)

3 (15.0%)

  1. Data are presented as mean ± standard deviation or as number (percentage). anti-CCP, anti-cyclic citrullinated peptide (antibodies); DAS28, disease activity score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RF, rheumatoid factor; Rx, treatment.